Search / Trial NCT00002446

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

Launched by SCHERING-PLOUGH · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Aids Related Opportunistic Infections Fluconazole Administration, Oral Antifungal Agents Candidiasis, Oral Pharyngeal Diseases Posaconazole

ClinConnect Summary

Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days. Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this study if you:
  • Are at least 18 years old.
  • Are HIV-positive.
  • Have thrush (oropharyngeal candidiasis).
  • Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms).
  • Are able to take study medication and return for clinic visits during the study.
  • Are expected to live for at least 2 months.
  • Exclusion Criteria
  • You will not be eligible for this study if you:
  • Have received protease inhibitors for the first time within 30 days prior to study entry.
  • Have received certain medications.
  • Have certain other types of fungal infections.
  • Have certain types of cancer.
  • Have received SCH 56592 within 3 months prior to study entry.
  • Are pregnant or breast-feeding.
  • Cannot take medications by mouth.
  • Are allergic to azole drugs.
  • Have certain medical conditions.
  • Have been in this study before.

About Schering Plough

Schering-Plough, a leading global biopharmaceutical company, is dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs across a range of therapeutic areas, including oncology, immunology, and infectious diseases. With a commitment to advancing healthcare through scientific excellence, Schering-Plough leverages cutting-edge technologies and collaborative partnerships to bring transformative treatments to patients worldwide. The company's robust pipeline, combined with its focus on patient-centric solutions, underscores its mission to improve health outcomes and enhance the quality of life for individuals facing complex health challenges.

Locations

Charleston, South Carolina, United States

Miami, Florida, United States

San Antonio, Texas, United States

Camden, New Jersey, United States

San Francisco, California, United States

Berkeley, California, United States

Detroit, Michigan, United States

Washington, District Of Columbia, United States

San Francisco, California, United States

Indianapolis, Indiana, United States

Brooklyn, New York, United States

Jacksonville, Florida, United States

Dallas, Texas, United States

Denver, Colorado, United States

Chicago, Illinois, United States

Jersey City, New Jersey, United States

Philadelphia, Pennsylvania, United States

St Michael, , Barbados

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials